<DOC>
	<DOC>NCT01844973</DOC>
	<brief_summary>This study is to evaluate the pharmacokinetics and safety of M518101 in male and female plaque psoriasis patients.</brief_summary>
	<brief_title>Study to Evaluate the Pharmacokinetics and the Safety of M518101 in Plaque Psoriasis Patients</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Who are able and willing to give signed informed consent Who are male or females aged 18 years or older with plaque psoriasis confirmed by the Investigator. Who have â‰¥20% of body surface area (BSA) afflicted with plaques Who are neither pregnant nor breastfeeding, nor plan to become pregnant during the study. Who have a history of allergy to vitamin D3 derivative preparations or a history of relevant drug hypersensitivity. BMI &gt; 32.0 kg/m2 Who are pregnant or lactating. Who have any renal or hepatic insufficiency, or clinically significant cardiac, renal or hepatic disease. Who are not deemed eligible as determined by medical history, physical examination or clinical laboratory safety tests. Who have clinically relevant history or presence of any disease or surgical history other than psoriasis which is likely to affect the conduct of the study. Whose serum calcium levels exceed the upper limit of reference range Who have used any investigational medicinal product and/or participated in any clinical study within 60 days of randomization. Who have taken any durg with known effects on calcium metabolism within 30days of randomization Who have been treated with any drug with a known risk of QT prolongation within 30days of randomization.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>